- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01000207
Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects
November 30, 2016 updated by: Novartis Vaccines
A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Pediatric Subjects
This study is to identify the preferred vaccine dosage (of antigen and adjuvant) and schedule (one or two administrations) of the cell-derived H1N1sw monovalent vaccine in healthy children/adolescents based on European Medicines Agency's Committee for Medicinal Products for Human Use (EMEA/CHMP) criteria, and safety and tolerability.
Study Overview
Status
Completed
Conditions
Detailed Description
This is a multi-center, randomized, single-blind, dose-ranging study.
Subjects were randomized at a 1:1 ratio to receive either 3.75μg of cell-derived H1N1sw vaccine formulated in half (i.e., half the content of the European-licensed adjuvanted seasonal influenza vaccine) MF59 adjuvant (3.75_halfMF59) or 7.5μg of cell-derived H1N1sw vaccine formulated with full MF59 (7.5_fullMF59).
Subjects were not informed of their allocated doses.
Two vaccinations were administered IM three weeks apart.
Subjects in both the vaccine groups were stratified into three age strata: 6 to 35 months, 3 to 8 years and 9 to 19 years.
Blood samples were collected at day 1 (baseline), three weeks after the first vaccination (day 22) and three weeks after the second vaccination (day 43).
Sera were tested by Hemagglutination Inhibition (HI) and Microneutralization (MN) assays.
Local and systemic reactions were collected for the first week following each injection using Diary Card (i.e., day 1 to day 7 and day 22 to day 28).
All adverse events (AE), serious adverse events (SAE), and AEs that led to withdrawal from the study and related prescription medications were collected for the entire study period.
Study Type
Interventional
Enrollment (Actual)
123
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kagoshima, Japan
- Sites 1,2,3,4,5
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 19 years (Child, Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy Japanese aged 6 months to 19 years
Exclusion Criteria:
- History of anaphylaxis, serious vaccine reactions, hypersensitivity to vaccine viral proteins or excipients
- Administration of adjuvanted influenza vaccine or suspected influenza disease within 3 month prior to study start
- Administration of any other vaccines within 4 weeks prior to enrollment expect for seasonal influenza vaccines within 1 week
- History of progressive or severe neurological disorders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Dose ranging
|
High dose group and low dose group of adjuvanted vaccines
|
Experimental: 2
Dose ranging
|
High dose group and low dose group of adjuvanted vaccines
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Seroprotection, GMRs and Seroconversion rate at Weeks 0, 3 and 6
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AEs, vital signs, laboratory tests
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
December 1, 2009
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
October 21, 2009
First Submitted That Met QC Criteria
October 21, 2009
First Posted (Estimate)
October 22, 2009
Study Record Updates
Last Update Posted (Estimate)
December 1, 2016
Last Update Submitted That Met QC Criteria
November 30, 2016
Last Verified
January 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V110_08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Swine-Origin Influenza A H1N1 Virus
-
Novartis VaccinesCompletedSwine-Origin Influenza A H1N1 VirusJapan
-
Novartis VaccinesCompletedSwine-Origin Influenza A H1N1 VirusJapan
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Swine-Origin A/H1N1 Influenza VirusFrance
-
Novartis VaccinesCompletedA New Flu Virus of Swine Origin | Pandemic Influenza A (H1N1)Argentina, Netherlands
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Swine-origin A/H1N1 InfluenzaFinland
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Swine-origin A/H1N1 InfluenzaFrance
-
SanofiCompletedInfluenza | Swine-origin A/H1N1 InfluenzaUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Swine-origin A/H1N1 InfluenzaUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Swine-origin A/H1N1 InfluenzaUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Swine-origin A/H1N1 InfluenzaFinland
Clinical Trials on Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
-
Novartis VaccinesCompleted
-
National Taiwan University HospitalUnknownSerology Analysis | Novel H1N1 Influenza Vaccination | Pediatric Haemato-oncology PatientsTaiwan
-
University of RochesterCompleted